{"title":"Cisplatin-induced ototoxicity in patients receiving concurrent chemoradiation in carcinoma cervix","authors":"Hanan M, Kutty Ckk, S. P, J. Mb","doi":"10.17727/jmsr.2022/10-26","DOIUrl":null,"url":null,"abstract":"Background: Weekly cisplatin at 40mg/m2 is the most common regimen followed in our institution. However, patients receiving cisplatin can experience high-frequency hearing loss due to its expansive toxicity profile, a side effect known as ototoxicity. The dearth of information on the extent and severity of cisplatin-associated ototoxicity prevents implementing a context-specific audiological monitoring program. The study aimed to determine the extent and severity of cisplatin ototoxicity in patients receiving concurrent chemoradiation in carcinoma cervix. Methods: Otoscopic examinations and audiological investigations were undertaken at regular intervals in patients undergoing concurrent chemoradiation for carcinoma cervix with single-agent cisplatin in the Department of Radiation Oncology, with the aid of the Department of ENT. All the audiological investigations were provided free of cost. Sixty-six patients who met the inclusion criteria were sent for audiological evaluation before the start of chemotherapy, immediately after chemotherapy completion and after one month following chemotherapy. Results: The study found that cisplatin was associated with high frequency, predominantly bilateral sensorineural hearing loss. Among 66 patients, seven patients (11%) developed cisplatin-induced hearing loss. However, most of the patients developed mild and minimal hearing loss. Conclusion: The study concluded that patients receiving concurrent chemoradiation for carcinoma cervix with cisplatin developed predominantly bilateral, high-frequency sensorineural hearing loss. However, most patients developed minimal or mild hearing loss.","PeriodicalId":32890,"journal":{"name":"Journal of Medical and Scientific Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical and Scientific Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17727/jmsr.2022/10-26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Weekly cisplatin at 40mg/m2 is the most common regimen followed in our institution. However, patients receiving cisplatin can experience high-frequency hearing loss due to its expansive toxicity profile, a side effect known as ototoxicity. The dearth of information on the extent and severity of cisplatin-associated ototoxicity prevents implementing a context-specific audiological monitoring program. The study aimed to determine the extent and severity of cisplatin ototoxicity in patients receiving concurrent chemoradiation in carcinoma cervix. Methods: Otoscopic examinations and audiological investigations were undertaken at regular intervals in patients undergoing concurrent chemoradiation for carcinoma cervix with single-agent cisplatin in the Department of Radiation Oncology, with the aid of the Department of ENT. All the audiological investigations were provided free of cost. Sixty-six patients who met the inclusion criteria were sent for audiological evaluation before the start of chemotherapy, immediately after chemotherapy completion and after one month following chemotherapy. Results: The study found that cisplatin was associated with high frequency, predominantly bilateral sensorineural hearing loss. Among 66 patients, seven patients (11%) developed cisplatin-induced hearing loss. However, most of the patients developed mild and minimal hearing loss. Conclusion: The study concluded that patients receiving concurrent chemoradiation for carcinoma cervix with cisplatin developed predominantly bilateral, high-frequency sensorineural hearing loss. However, most patients developed minimal or mild hearing loss.